Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mitchell Dann Insider Profile
4 Followers
Mitchell Dann, Director at Urologix, holds 602.39K shares in Urologix (Ticker: ULGX), holds 1.66M shares in Baxano Surgical (Ticker: BAXSQ).
Profitable Transactions
1 out of 4 Profitable Transactions
Average Return
-25.20%
Average return per transaction
Time Frame
Compare to
Insider Roles
Director
Roles that Mitchell Dann holds in companies
Most Profitable Insider Trade
Stock:
Baxano Surgical
(BAXSQ)
(BAXSQ)
Rating:Informative Buy
Date:May 27, 2010 - May 27, 2011
Return:+55.80%
The most profitable trade made by Mitchell Dann
Mitchell Dann's Trading History
Urologix
Nov 21, 2014
Director
Uninformative Buy
―
$6.02K
Baxano Surgical
May 27, 2010
―
Informative Buy
36.88K
―
List of latest transactions for each holding click on a transaction to see Mitchell Dann's performance on stock
You May Also Like
Mitchell Dann insider profile FAQ
What is the percentage of profitable transactions made by Mitchell Dann?
The percentage of profitable transactions made by Mitchell Dann is 25%.
What is the average return per transaction made by Mitchell Dann?
The average return per transaction made by Mitchell Dann is -25.20%.
What stocks does Mitchell Dann hold?
Mitchell Dann holds: ULGX, BAXSQ stocks.
What was Mitchell Dann’s latest transaction?
Mitchell Dann latest transaction was an Uninformative Buy of ―.
What was Mitchell Dann's most profitable transaction?
Mitchell Dann’s most profitable transaction was an Informative Buy of BAXSQ stock on May 27, 2010. The return on the trade was 55.80%.
What is Mitchell Dann's role in Urologix?
Mitchell Dann's role in Urologix is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.